Tag Archives: Healthcare

Liver Cirrhosis- Market Insights, Epidemiology and Market Forecast-2023

Liver Cirrhosis

Summary:

DelveInsights Liver Cirrhosis – Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Crohns disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Liver Cirrhosis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Liver Cirrhosis till 2023.

Scope:

Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
It also provides Liver Cirrhosis for United States, EU5 and Japan from 2013 and forecasted Market to 2023.

Browse The full Market Research Report @ http://bit.ly/2bXAzMr

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global Liver Cirrhosis market.
Identifying patient populations in the global Liver Cirrhosismarket to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Liver Cirrhosis therapeutics in each of the markets covered.
To understand the future market competition in the global Liver Cirrhosis therapeutics market and Insightful review of the key market drivers and barriers.

Best Selling Market Reports :

Europe Cod Liver Oil Market Report 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2016

Traumatic Brain Injury- Market Insights, Epidemiology and Market Forecast-2023

 

Advertisements

Vaccines Market by Technology , Disease Indication , End User & Type – Forecasts to 2021

Vaccines Market

Summary:

The vaccines market is expected to reach USD 48.03 billion by 2021 from USD 32.24 billion in 2016 at a CAGR of 8.3%. The global vaccines market is segmented based on technology, type, disease indication, end-users, and regions. The conjugate vaccines segment is expected to register the highest growth rate in the vaccines market, by technology, during the forecast period. The high growth in this segment is attributed to the increasing company investments in development of new vaccines.

Based on end-users, the vaccines market is segmented into paediatrics and adults. The paediatrics segment is expected to account for the largest share of the market in 2016. Increasing prevalence of diseases in children and the rising number of awareness programs to promote vaccination will drive the growth of this market.
Geographically, the vaccines market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by rising government funding for vaccine research in the North American countries.

The major factors contributing to the growth of the vaccines market include high prevalence of diseases, rising government and nongovernment funding for vaccine development, and increasing focus on immunization programs. Furthermore, increasing R&D spending and new vaccine development activities by companies is another major factor driving the growth of this market.
Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.
The major players in this market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), and Serum Institute of India Pvt. Ltd. (India).

The Market Report provides Insights On The Following Pointers:

• Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccines market. The report analyses the vaccines market by technology, type, disease indication, end-users, and regions
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccines market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the vaccines market
• Market Development: Comprehensive information about emerging markets. This report analyses the market for various vaccines across geographies
• Market Diversification: Exhaustive information about new vaccines, untapped geographies, recent developments, and investments in the vaccines market

Browse The full Market Research Report @ http://goo.gl/IwtUeI

Reasons To Buy The Market Research Report:

This Market Research report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

Best Selling Reports :

Global Pneumococcal Vaccines Sales Market Report 2021

Global MMRV Vaccines Sales Market Report 2021

Global Meningococcal Vaccines Sales Market Report 2021

Mayo Clinic – Strategic SWOT Analysis Review

Mayo Clinic

SUMMARY

Mayo Clinic – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

– Business description A detailed description of the companys operations and business divisions.
– Corporate strategy GlobalDatas summarization of the companys business strategy.
– SWOT analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
– Company history Progression of key events associated with the company.
– Major products and services A list of major products, services and brands of the company.
– Key competitors A list of key competitors to the company.
– Key employees A list of the key executives of the company.
– Executive biographies A brief summary of the executives employment history.
– Key operational heads A list of personnel heading key departments/functions.
– Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
– Key manufacturing facilities A list of key manufacturing facilities of the company.

Browse full report @ http://www.aarkstore.com/pharmaceuticals-healthcare/176704/mayo-clinic-strategic-swot-analysis-review

Highlights

Mayo Clinic (Mayo) formerly known as Mayo Clinic Jacksonville is a not-for-profit healthcare organization. The organization provides comprehensive medical facilities and programs related to healthcare education, and research and patient care services. It provides treatments for diseases such as cancer, bipolar disorder, brachial plexus injury, tumors, burning mouth syndrome, eating disorders, epilepsy, infectious diseases, lung diseases, melanoma, Alzheimers and Parkinsons disease, temporomandibular joint (TMJ) disorders, womens health, Wilsons disease and Wolff-Parkinson-White (WPW) syndrome, among others. Mayo operates through its various medical departments that include aerospace medicine, allergy, breast cancer, emergency medicine, medical genetics, pathology, radiology, oncology, neurology, nephrology, ophthalmology and others. Mayo Clinic is headquartered in Jacksonville, Florida, the US.

Reasons to Buy

– Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
– Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services and business strategy.
– Understand and respond to your competitors business structure and strategies with GlobalDatas detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
– Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.

Best Selling Reports :

Mayo Clinic US – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Singapore Telecommunications Limited (Z74) – Financial and Strategic SWOT Analysis Review

Mind C.T.I. Ltd. (MNDO) – Financial and Strategic SWOT Analysis Review

 

US to Remain World’s Leading Diagnostic X-Ray Systems Market to 2020

MediPoint: Diagnostic X-ray Imaging Report

The US is the world’s largest market for diagnostic X-ray systems, accounting for over 29% of global revenues in 2013. Despite the emergence of China, it will continue to hold the leading share of 25%+ by 2020. As reimbursement for X-ray examinations currently incurs lower physician fees than computerised tomography and magnetic resonance imaging scans in the US, there is less financial incentive for physicians to perform X-ray exams. On the other hand, the implementation of various healthcare reforms means that cuts in reimbursement for advanced imaging modalities could potentially have a positive impact on the use of X-ray procedures, and therefore on the sale of systems.

MediPoint: Diagnostic X-ray Imaging – Global Analysis and Market Forecasts report discusses the future of diagnostic X-ray imaging in the face of rapid technological advancements and other progressive imaging modalities.

Key questions answered in this report:

  • What role will diagnostic X-ray imaging play in the forecast period to tackle this global issue?
  • How will changing demographics and lifestyles affect the utilization of diagnostic X-ray imaging?
  • What are the significant unmet needs?
  • What is the scope for more innovation and what are the end-users looking for in their products?
  • Which countries expect to see the most growth and what do the hurdles opportunities lay?
  • What percent of global profits are from emerging markets and how will this change in the future?

Gain unique insight into how healthcare professionals are reacting to developments within the industry.

Report available with http://www.aarkstore.com  | Publisher : GlobalData

Global Biosimilars Market Value Could Hit $55 Billion by 2020

Biosimilars – Regulatory Framework and Pipeline Analysis

The value of the global biosimilars market is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, with growth primarily driven by a promising pipeline in active developments and government efforts to reduce healthcare spending. Biologics currently account for between 17–20% of the pharmaceutical arena, with a value of nearly $200 billion, and these products may replace 70% of chemical drugs in the next two decades. The 30% to 50% reduction in biosimilar prices compared with branded biologics could lead to considerable savings in healthcare expenditure.

Biosimilars – Regulatory Framework and Pipeline Analysis report provides a regulatory overview and market outlook for biosimilars, both globally and across the major markets of Europe, the US, India, South Korea, Japan, and China.

http://www.aarkstore.com

The report will allow you to:

  • Understand the regulatory requirements and framework that facilitates effective product development strategy
  • Analyse the details of the clinical pipeline that includes late stage products, Phase II, and Phase I products
  • Examine the biosimilars pipeline, evaluate the products that are highly targeted, analyse the focused indications, therapy areas and the mechanism of actions
  • Understand the pipeline that will help in targeting products for development, rate current products and predict the competition

Find out how Biosimilars are providing a base for reducing the healthcare expenditure in developed markets.

Pipeline Advancements Fuelled Mid-Cap Biotech Research and Development Spend in 2014

PharmaLeaders: Mid-Cap Biotechnology Benchmark Report – Sales Forecasts and Product Valuations of Innovative Biotechs

The combined spend on research and development for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spender Regeneron. The company led the way with R&D expenses of $860 million in 2013, further analysis shows that Regeneron’s R&D expenses grew by 47.9% year-to-year to $1.3 billion in 2014. Vertex had the second largest R&D outlay among the peer group, spending $855.5 million in 2014, representing a 3% decrease from 2013. This resulted from the company completing the TRAFFIC and TRANSPORT clinical trials evaluating VX-809, a combination product of lumacaftor and ivacaftor for treating cystic fibrosis.

Mid-Cap Biotechnology Benchmark Report applies a proprietary ranking methodology to compare the competitive positions of 35 mid-cap biotechnology companies on 14 financial metrics. Key questions answered:

  • What specific strategies are innovative biotech companies employing to gain market share?
  • What therapeutic areas are biotech companies allocating their R&D budgets?
  • Which trends will affect the sector moving forward?
  • How does my pipeline and commercialisation strategy match up against the competition?
  • What specific business development activities are taking place, in terms of partnerships or M&A?
  • What particular enabling technologies and drug platforms are companies developing?
  • How are companies maximising their capital spend to gain competitive advantage?

Benchmark your company’s performance against a similar peer group to assess areas of strength/weakness.

Anjali Kalan
anjali@aarkstore.com

Yet another alternative to test breast cancer

Quest Diagnosis, a medical testing company, announced recently of developing a new genetic test to  diagnose breast cancer. The test has been named as BRC Advantage.

While reading this news, my mind took me into my childhood memories. I was 8 when my loving grandmother passed away. She died at a very early age of 50 as she was late in diagnosing her breast cancer. If she was a little more aware about the various breast cancer tests available, she might have lived longer.

Womens Health

Womens Health

The new test developed is capable of identifying BRCA1 (BReast CAncer gene one) and BRCA2 (BReast CAncer gene two), genes responsible for normal growth and functioning of the breast cells. But any kinds of abnormalities (mutations) in these cells can lead to an increased risk of breast or ovarian cancer.

Earlier a company, Myriad Genetics had a patent on these two BRCA genes which gave the company an exclusive holding on testing any mutations in these genes.

But a recent US Supreme Court ruling has invalidated this patent thus making the two BRCA genes available to other companies for developing their own tests. Breast Cancer Therapies Markets

And why not? A naturally occurring gene is a nature’s product and not a mere patent. And very  soon the Supreme Court’s decision seems to be showing results with Quest Diagnosis coming with its first such test called BRC Advantage. The test is currently available in 49 US states and more than 2100 service centers. Quest Diagnosis hopes to increase the availability of these tests at high risking populations.

Reading about this new breast cancer test, questions still keep pouring in my mind that even after enough number of tests available, are we women actually aware about them?

%d bloggers like this: